Hindustan Bio Sciences Announces Capital Restructuring and FY26 Results

Revenue fell to Rs 73.71 lakh; Net loss recorded at Rs 7.89 lakh.

Reader Takeaway: The company is attempting a balance sheet cleanup, but must clear NCLT hurdles and AGM approvals.

What just happened

Hindustan Bio Sciences Ltd released its 34th Annual Report for the fiscal year ending March 31, 2026. A centerpiece of the report is a proposed Special Resolution to reduce the company's share capital by writing off Rs 1.13 crore in accumulated losses against existing paid-up capital. Following this, the company will consolidate its shares, changing the face value from Rs 2 to Rs 10 per share.

Why this matters

The capital reduction is a strategic attempt to re-align the company's capital with its remaining assets. Management expects this move to provide greater flexibility for future fundraising and offer a more accurate financial picture to investors. Shareholders will receive 9 new equity shares of Rs 10 each for every 100 equity shares of Rs 2 held before the record date.

Financial Snapshot

For FY 2025-2026, the company reported a decline in revenue to Rs 73.71 lakh, compared to Rs 81.33 lakh in the previous fiscal year. The company swung into a net loss of Rs 7.89 lakh from a net profit of Rs 10.07 lakh in FY25. Basic and diluted EPS stands at (0.08) compared to 0.10 in the prior year.

Board and Governance

The company has scheduled its 34th Annual General Meeting for September 30, 2026, at its Hyderabad office. The Board has recommended the re-appointment of Smt. Uma Jampana as Director. Additionally, Mr. Shailendra Vyas assumed the role of Company Secretary and Compliance Officer on August 1, 2025.

What to track next

Investors should closely monitor the outcome of the Special Resolution at the upcoming AGM. The implementation of this scheme is also subject to approval from the National Company Law Tribunal (NCLT).